Apatinib mesylate tablet in the treatment of advanced malignant melanoma

作者：Yang, Lingge; Zhu, Huiyan; Luo, Peng; Chen, Shiqi; Xu, Yu; Wang, Chunmeng^*

来源：OncoTargets and Therapy, 2018, 11: 5333-5338.

DOI：10.2147/OTT.S175507

• apatinib
• malignant melanoma
• targeted therapy
• adverse reaction
• efficacy

Background: Observing and studying clinical efficacy and safety of apatinib mesylate tablet in the treatment of advanced malignant melanoma (MM).
Methods: Retrospectively analyzing the clinical data of 22 patients with metastatic MM who had failed conventional chemotherapy from June 2016 to January 2018. All patients took 500 mg of apatinib mesylate tablets per day. The efficacy should be evaluated according to RECIST 1.1 criteria. Adverse events (AEs) should be graded according to NCI-CTCAE 4.0.
Results: There were two cases of partial remission (PR), 11 of stable disease (SD) and nine of progressive disease (PD) in the 22 patients with advanced MM, where the objective remission rate (ORR) was 9.1% and the disease control rate (DCR) was 59.1%. The median progression-free survival (PFS) was 7.5 months, and the 6-month progression-free survival rate (PFR) was 54.7%. Six patients died and the overall survival (OS) was not reached. AEs were controllable and all were in Grade 1-3.
Conclusion: Apatinib mesylate tablets have a certain curative effect on patients with malignant melanomas of Stage IV who failed conventional chemotherapy. Apatinib mesylate tablets at a daily dose of 500 mg are well tolerated by most patients.

• 出版日期2018
• 单位复旦大学